Journal
PARKINSONISM & RELATED DISORDERS
Volume 13, Issue 8, Pages 466-479Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.parkreldis.2007.06.015
Keywords
levodopa; dopamine agonists; monoamine oxidase inhibitors; mode of action
Categories
Ask authors/readers for more resources
Most treatment advances in PD have been based on restoring dopaminergic input. The development of levodopa was the first breakthrough and, since then, other compounds have been developed. Each antiparkinsonian medication has its own profile of efficacy and adverse effects, and these can largely be explained by their modes of action. As patients receive a number of different compounds, physicians should be aware of the differences of agents and understand how these differences may relate to clinical practice. This article reviews the three main classes of dopaminergic PD therapy (levodopa, monoamine oxidase inhibitors and dopamine agonists). (c) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available